Skip to main content
MedPathMedPath Home
Clinical Trials/NCT01451255
NCT01451255
Completed
Not Applicable

Early Detection of Pulmonary Arterial Hypertension Using Cardiac Magnetic Resonance Imaging

Mayo Clinic2 sites in 1 country90 target enrollmentAugust 2011
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsPulmonary HypertensionPulmonary Arterial Hypertension

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pulmonary Hypertension
Sponsor
Mayo Clinic
Enrollment
90
Locations
2
Status
Completed
Last Updated
10 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

Cardiac magnetic resonance imaging has emerged as a potential valuable test for the early detection of Pulmonary Arterial Hypertension. A number of reports have provided some preliminary evidence that Pulmonary Artery (PA) stiffness may be accurately detected by imaging of the pulmonary artery in order to measure PA stiffness. In addition, cardiac MRI could play provide early and effective treatment for Pulmonary Arterial Hypertension (PAH).

Registry
clinicaltrials.gov
Start Date
August 2011
End Date
June 2014
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Brian Shapiro

Principal Investigator

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

  • •Consecutive patients aged ≥ 18 years with PAH as dictated by a comprehensive examination and echocardiography will be included for enrollment.

Exclusion Criteria

  • •Age \< 18 years
  • •Pregnancy
  • •Mechanical ventilation
  • •Acute or chronic renal failure (creatinine clearance \< 30 ml/min or requiring renal replacement therapy)
  • •Inability to perform MRI (i.e. claustrophobia, severe obesity (\> 150 kg), device incompatible with MRI)
  • •Significant arrhythmia that precludes adequate ECG-gating for the MRI (i.e. atrial fibrillation with highly variable cycle lengths)
  • •Prior heart or lung transplantation
  • •Left ventricular systolic (ejection fraction \< 50%) or diastolic failure (based on Framingham criteria for heart failure with preserved ejection fraction)
  • •Significant left-sided valvular disease (≥ moderate aortic stenosis, mitral stenosis, aortic regurgitation, mitral regurgitation) or prior valve surgery

Outcomes

Primary Outcomes

Not specified

Study Sites (2)

Loading locations...

Similar Trials

Completed
Not Applicable
The Early Recognition of Pulmonary Arterial HypertensionPulmonary Arterial Hypertension
NCT00609349Medical University of Graz52
Completed
Not Applicable
Cardiac Magnetic Resonance Imaging and Pulmonary PerfusionPulmonary Hypertension
NCT01100008University Hospital, Toulouse29
Enrolling By Invitation
Not Applicable
Non-contrast Enhanced Cardiac Magnetic Resonance Imaging in the Diagnosis and Classification of Pulmonary HypertensionPulmonary HypertensionElevated Mean Pulmonary Arterial PressureNormal Mean Pulmonary Arterial Pressure
NCT01725763Medical University of Graz150
Completed
Phase 1
Novel MRI Techniques in the Evaluation of Pulmonary Vascular DiseasePulmonary Hypertension
NCT02026531Sheffield Teaching Hospitals NHS Foundation Trust9
Recruiting
Not Applicable
Study of Cardiac MRI in the Follow up Assessment of Patients With PAH (EVITA)Pulmonary Arterial Hypertension
NCT02845518Central Hospital, Nancy, France180